UBS Maintains Neutral on Exelixis, Lowers Price Target to $38

Benzinga · 07/30/2025 15:09
UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and lowers the price target from $43 to $38.